Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 7:54 p.m. and Nov. 22, 2024, 7:54 p.m. from: Preclinical Services.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


On a roll, CDMO Samsung Bio strikes $668M production tie-up with European pharma

Document Date: Nov. 20, 2024, 7:02 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: Back in July, the CDMO announced a $ 1.05 billion manufacturing partnership with an unnamed U.S. drugmaker set to run through 2030. The company followed up that reveal with news of a $ 1.2 billion contract with another anonymous, Asia - based pharmaceutical company in October. The latter deal is set to last through December 2037. Prior to those agreements, Samsung Bio expanded a long-running partnership with Belgium's UCB to manufacture an anti-tau candidate in progressive supranuclear palsy and retooled a deal with Baxter Healthcare to provide unspecified production services through 2034. While many other CDMOs have struggled to come to grips with the post-pandemic contracting industry, Samsung Bio has largely avoided headwinds since rising to prominence several years ago.
Document Source: https://www.fiercepharma.com/pharma/samsung-bio-inks-production-tie-another-unnamed-pharma-time-worth-668m (archive.org page / archive.org listing)


On a roll, CDMO Samsung Bio strikes $668M production tie-up with European pharma

Document Date: Nov. 20, 2024, 7:02 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: Rather than commenting on the latest production tie-up directly, the company's CEO, John Rim, pledged in a statement to continue pouring the proceeds from Samsung Bio's contracting projects back into the CDMO's production capabilities. Following a slate of high-value deals this year, Samsung Biologics is now partnered with 17 of the world's top 20 pharmaceutical companies, the manufacturer said in a release. Next up, the CDMO is adding antibody-drug conjugate services, including process development and conjugation, to its portfolio of offerings, Samsung Bio said. Samsung Biologics has been in the habit of disclosing high-dollar contracts with unnamed customers in recent months. Back in July, the CDMO announced a $ 1.05 billion manufacturing partnership with an unnamed U.S. drugmaker set to run through 2030.
Document Source: https://www.fiercepharma.com/pharma/samsung-bio-inks-production-tie-another-unnamed-pharma-time-worth-668m (archive.org page / archive.org listing)


On a roll, CDMO Samsung Bio strikes $668M production tie-up with European pharma

Document Date: Nov. 20, 2024, 7:02 p.m. / Source: Fierce Pharma
Activity Class: PartnershipActivity
Partnership: Document Extract: Samsung Biologics has been in the habit of disclosing high-dollar contracts with unnamed customers in recent months. Back in July, the CDMO announced a $ 1.05 billion manufacturing partnership with an unnamed U.S. drugmaker set to run through 2030. The company followed up that reveal with news of a $ 1.2 billion contract with another anonymous, Asia - based pharmaceutical company in October. The latter deal is set to last through December 2037. Prior to those agreements, Samsung Bio expanded a long-running partnership with Belgium's UCB to manufacture an anti-tau candidate in progressive supranuclear palsy and retooled a deal with Baxter Healthcare to provide unspecified production services through 2034.
Document Source: https://www.fiercepharma.com/pharma/samsung-bio-inks-production-tie-another-unnamed-pharma-time-worth-668m (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.